Calliditas
IPOExpanding treatment options for patients with rare diseases.
Calliditas was founded in 2004, is headquartered in Stockholm, Sweden, and lists 51–200 employees.
- Headquarters
- Stockholm
- Employees
- 51–200
- Founded
- 2004
- Business Model
- B2B
- Website
- calliditas.se
- Type
- Public
About
Calliditas Therapeutics is a commercial-stage specialty biopharmaceutical company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments for rare diseases with significant unmet medical needs. Founded in 2004, the company pioneered TARPEYO (budesonide delayed-release capsules), the first and only FDA-approved treatment specifically designed for IgA nephropathy, a rare kidney disease. Calliditas markets TARPEYO in the United States and licenses the drug globally, while also advancing a pipeline of NOX enzyme inhibitors for fibrotic and oncological conditions. The company was acquired by Japanese pharmaceutical group Asahi Kasei in 2024.
Summary
Calliditas is a Biotech company based in Stockholm, Sweden, founded in 2004. It lists 51–200 employees.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Exit History
Jun 2020
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/calliditas"><img src="https://indexed.vc/api/badge/company/calliditas" alt="Calliditas on Indexed.vc" width="260" height="76" /></a>